Jessica R. C. Priestley

Jessica R. C. Priestley

Auto-generated profile, based on publicly available information

Jessica R. C. Priestley

Division of Human Genetics, Department of Pediatrics Children's Hospital of Philadelphia Philadelphia Pennsylvania USA

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 May 2009 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SWStephanie Wengert Watts
Stephanie Wengert Watts
JPJessica R. C. Priestley
Jessica R. C. Priestley
JTJanice M. Thompson
Janice M. Thompson
Serotonin (5-hydroxytryptamine, 5-HT) was named for its source (sero-) and ability to modify smooth muscle tone (tonin). The biological effects of 5-HT are believed to be carried out by stimulation of serotonin receptors at the plasma membrane. Serotonin has recently been shown to be synthesized in vascular smooth muscle and taken up from external sources, placing 5-HT inside the cell. The enzyme transglutaminase uses primary amines such as 5-HT to covalently modify proteins on glutamine residues. We tested the hypothesis that 5-HT is a substrate for transglutaminase in arterial vascular smooth muscle, with protein serotonylation having physiological function. The model was the rat aorta and cultured aortic smooth muscle cells. Western analysis demonstrated that transglutaminase II was present in vascular tissue, and transglutaminase activity was observed as a cystamine-inhibitable incorporation of the free amine pentylamine-biotin into arterial proteins. Serotonin-biotin was incorporated into α -actin, β-actin, γ-actin, myosin heavy chain and filamin A as shown through tandem mass spectrometry. Using antibodies directed against biotin or 5-HT, immunoprecipitation and immunocytochemistry confirmed serotonylation of smooth muscle α–actin. Importantly, the α-actin-dependent process of arterial isometric contraction to 5-HT was reduced by cystamine. 5-HT covalently modifies proteins integral to contractility and the cytoskeleton. These findings suggest new mechanisms of action for 5-HT in vascular smooth muscle and consideration for intracellular effects of primary amines.

1 June 2008 in British Journal of Pharmacology
Verified
Journal Article
Open access
PDF file
WNW Ni
W Ni
TGT J Geddes
T J Geddes
JPJ R C Priestley
J R C Priestley
TST Szasz
T Szasz
DKD M Kuhn
D M Kuhn
SWStephanie Wengert Watts
Stephanie Wengert Watts
Background and purpose: 5‐HT is a vasoconstrictor exhibiting enhanced effects in systemic arteries from subjects with cardiovascular disease. The effect of endogenous 5‐HT on arteries is controversial, because the concentration of free circulating 5‐HT is low and a 5‐hydroxytryptaminergic system has not been identified in peripheral arteries. We hypothesized that a local 5‐hydroxytryptaminergic system (including 5‐HT synthesis, metabolism, uptake and release) with physiological function exists in peripheral arteries.Experimental approach: The presence of key components of a 5‐hydroxytryptaminergic system in rat aorta and superior mesenteric artery was examined using western blot analyses, immunohistochemistry and immunocytochemistry. The function of the rate‐limiting enzyme in 5‐HT biosynthesis, tryptophan hydroxylase (TPH), and 5‐HT transporter was tested by measuring enzyme activity and 5‐HT uptake, respectively. Isometric contraction of arterial strips was used to demonstrate the function of released endogenous 5‐HT in arterial tissues.Key results: mRNA for TPH‐1 was present in arteries, with low levels of TPH protein and TPH activity. Expression and function of MAO A (5‐HT metabolizing enzyme) was supported by immunohistochemistry, western analyses and the elevation of concentrations of 5‐hydroxyindoleacetic acid (5‐HT metabolite) after exposure to exogenous 5‐HT. The 5‐HT transporter was localized to the plasma membrane of freshly isolated aortic smooth muscle cells. Peripheral arteries actively took up 5‐HT in a time‐dependent and 5‐HT transporter‐dependent manner. The 5‐HT transporter substrate, (+)‐fenfluramine, released endogenous 5‐HT from peripheral arteries, which potentiated noradrenaline‐induced arterial contraction.Conclusions and implications: This study revealed the existence of a local 5‐hydroxytryptaminergic system in peripheral arteries.British Journal of Pharmacology (2008) 154, 663–674; doi:10.1038/bjp.2008.111; published online 14 April 2008

8 May 2023 in JCI Insight
Verified
Journal Article
Open access
PDF file
SSSarah E. Sheppard
Sarah E. Sheppard
MMMichael March
Michael March
CSChristoph Seiler
Christoph Seiler
LMLeticia S. Matsuoka
Leticia S. Matsuoka
SKSophia E. Kim
Sophia E. Kim
HHHakon Hakonarson
Hakon Hakonarson
Central conducting lymphatic anomaly (CCLA) due to congenital maldevelopment of the lymphatics can result in debilitating and life-threatening disease with limited treatment options. We identified 4 individuals with CCLA, lymphedema, and microcystic lymphatic malformation due to pathogenic, mosaic variants in KRAS . To determine the functional impact of these variants and identify a targeted therapy for these individuals, we used primary human dermal lymphatic endothelial cells (HDLECs) and zebrafish larvae to model the lymphatic dysplasia. Expression of the p.Gly12Asp and p.Gly13Asp variants in HDLECs in a 2‑dimensional (2D) model and 3D organoid model led to increased ERK phosphorylation, demonstrating these variants activate the RAS/MAPK pathway. Expression of activating KRAS variants in the venous and lymphatic endothelium in zebrafish resulted in lymphatic dysplasia and edema similar to the individuals in the study. Treatment with MEK inhibition significantly reduced the phenotypes in both the organoid and the zebrafish model systems. In conclusion, we present the molecular characterization of the observed lymphatic anomalies due to pathogenic, somatic, activating KRAS variants in humans. Our preclinical studies suggest that MEK inhibition should be studied in future clinical trials for CCLA due to activating KRAS pathogenic variants.

1 September 2013 in Microvascular Research
Verified
Journal Article
Closed access
JPJessica R.C. Priestley
Jessica R.C. Priestley
MBMatthew W. Buelow
Matthew W. Buelow
SMScott T. McEwen
Scott T. McEwen
BWBrian D. Weinberg
Brian D. Weinberg
MDMelanie Delaney
Melanie Delaney
JLJulian H. Lombard
Julian H. Lombard

28 April 2023 in Genetics in Medicine
Verified
Journal Article
Closed access
JPJessica R.C. Priestley
Jessica R.C. Priestley
ADAshish R. Deshwar
Ashish R. Deshwar
HMHarsha Murthy
Harsha Murthy
MDMaria D. D’aGostino
Maria D. D’aGostino
LDLucie Dupuis
Lucie Dupuis
EBElizabeth J. Bhoj
Elizabeth J. Bhoj

9 June 2023 in American Journal of Medical Genetics Part C: Seminars in Medical Genetics
Verified
Journal Article
Closed access
JPJessica R. C. Priestley
Jessica R. C. Priestley
ARAlyssa L. Rippert
Alyssa L. Rippert
CCCourtney Condit
Courtney Condit
KIKosuke Izumi
Kosuke Izumi
SKStaci Kallish
Staci Kallish
TDTheodore Drivas
Theodore Drivas